MA45831B1 - Anticorps monoclonaux anti-punaises de lit et leurs procédés de production et d'utilisation - Google Patents

Anticorps monoclonaux anti-punaises de lit et leurs procédés de production et d'utilisation

Info

Publication number
MA45831B1
MA45831B1 MA45831A MA45831A MA45831B1 MA 45831 B1 MA45831 B1 MA 45831B1 MA 45831 A MA45831 A MA 45831A MA 45831 A MA45831 A MA 45831A MA 45831 B1 MA45831 B1 MA 45831B1
Authority
MA
Morocco
Prior art keywords
methods
monoclonal antibodies
bedbug
production
antigen
Prior art date
Application number
MA45831A
Other languages
English (en)
Other versions
MA45831A (fr
Inventor
William John Hall
Min Wang
Original Assignee
Redcoat Solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Redcoat Solutions Inc filed Critical Redcoat Solutions Inc
Publication of MA45831A publication Critical patent/MA45831A/fr
Publication of MA45831B1 publication Critical patent/MA45831B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B22F1/05—Metallic powder characterised by the size or surface area of the particles
    • B22F1/054—Nanosized particles
    • B22F1/0545—Dispersions or suspensions of nanosized particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G01N33/54387—Immunochromatographic test strips
    • G01N33/54388—Immunochromatographic test strips based on lateral flow
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/0004—Preparation of sols
    • B01J13/0043—Preparation of sols containing elemental metal
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F2301/00—Metallic composition of the powder or its coating
    • B22F2301/25—Noble metals, i.e. Ag Au, Ir, Os, Pd, Pt, Rh, Ru
    • B22F2301/255—Silver or gold
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F2304/00—Physical aspects of the powder
    • B22F2304/05—Submicron size particles
    • B22F2304/054—Particle size between 1 and 100 nm
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F2304/00—Physical aspects of the powder
    • B22F2304/05—Submicron size particles
    • B22F2304/056—Particle size above 100 nm up to 300 nm
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
    • G01N2333/43552—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from insects
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des anticorps monoclonaux anti-punaises de lit et leurs fragments de liaison à l'antigène, ainsi que des compositions et des kits les contenant. La présente invention concerne également des procédés de production d'anticorps monoclonaux et leurs fragments de liaison à l'antigène et leurs procédés d'utilisation pour détecter des punaises de lit.
MA45831A 2015-10-21 2016-10-21 Anticorps monoclonaux anti-punaises de lit et leurs procédés de production et d'utilisation MA45831B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562244189P 2015-10-21 2015-10-21
PCT/US2016/058300 WO2017070603A1 (fr) 2015-10-21 2016-10-21 Anticorps monoclonaux anti-punaises de lit et leurs procédés de production et d'utilisation

Publications (2)

Publication Number Publication Date
MA45831A MA45831A (fr) 2019-06-12
MA45831B1 true MA45831B1 (fr) 2023-10-31

Family

ID=58558142

Family Applications (1)

Application Number Title Priority Date Filing Date
MA45831A MA45831B1 (fr) 2015-10-21 2016-10-21 Anticorps monoclonaux anti-punaises de lit et leurs procédés de production et d'utilisation

Country Status (13)

Country Link
US (2) US10768172B2 (fr)
EP (2) EP4273235A3 (fr)
AU (2) AU2016342373B2 (fr)
CA (1) CA3041460A1 (fr)
ES (1) ES2953484T3 (fr)
HR (1) HRP20231035T1 (fr)
HU (1) HUE063822T2 (fr)
MA (1) MA45831B1 (fr)
MD (1) MD3365367T2 (fr)
MX (1) MX2018004986A (fr)
PL (1) PL3365367T3 (fr)
RS (1) RS64530B1 (fr)
WO (1) WO2017070603A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3370515T (lt) 2015-10-21 2022-05-10 Redcoat Solutions, Inc. Patalinių blakių aptikimo įrenginys
RS64530B1 (sr) * 2015-10-21 2023-09-29 Redcoat Solutions Inc Monoklonalna antitela protiv krevetnih stenica i postupci za njihovo pravljenje i upotrebe
EP4056033B1 (fr) 2017-05-22 2023-09-06 Corteva Agriscience LLC Détection sélective de punaises de lit
EP3883376A4 (fr) 2018-11-21 2022-08-03 Corteva Agriscience LLC Détection sélective des punaises des lits

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US20010051350A1 (en) 1995-05-02 2001-12-13 Albert Nazareth Diagnostic detection device and method
AU4562599A (en) 1998-06-12 1999-12-30 New Horizons Diagnostics, Inc. Colloidal colorimetric flow through and lateral flow assays utilizing soluble submicron particles
WO2001027612A2 (fr) * 1999-10-12 2001-04-19 Connex Gesellschaft Zur Optimierung Von Forschung Und Entwicklung Mbh Test rapide immuno-chromatographique pour la detection de micro-organismes acido-resistants dans les selles
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
US7214542B2 (en) 2003-01-30 2007-05-08 Michael Hutchinson Method of processing assay test results
US7220597B2 (en) 2003-01-30 2007-05-22 Zin Benedict L Assay test device and method of making same
US7482128B2 (en) * 2003-03-27 2009-01-27 Heska Corporation Anti-feline albumin antibodies
US20080312425A1 (en) 2004-08-30 2008-12-18 Lonza Biologics Plc. Ion Exchange Chromatography and Purification of Antibodies
US7727734B1 (en) * 2005-07-27 2010-06-01 Cytosignet, Inc. Detection and measurement of blood-feeding activity
US7591099B2 (en) 2005-08-30 2009-09-22 Ecolab Inc. Bed bug monitor
WO2008051501A2 (fr) 2006-10-23 2008-05-02 Dow Agrosciences Llc Techniques de détection, de surveillance et de contrôle des parasites de literie
AU2013200548B2 (en) 2006-10-23 2015-06-18 Ecolab Usa Inc. Bedbug detection, monitoring and control techniques
US20100273177A1 (en) 2006-12-08 2010-10-28 Piasio Roger N Methods and Devices for Testing Saliva
EP1933145B1 (fr) 2006-12-11 2011-09-28 AraGen Biotechnology Co. Ltd. Détection rapide immunochromatographique par amplification du signal d'or colloïdal
US7691980B2 (en) 2007-01-09 2010-04-06 Bio-Rad Laboratories, Inc. Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers
EP2134852A4 (fr) 2007-03-13 2010-04-28 Nat Jewish Health Procédés de génération d'anticorps
US8435461B2 (en) 2007-04-20 2013-05-07 Quidel Corporation Analytical devices with integrated desiccant
US20090155921A1 (en) 2007-12-12 2009-06-18 Arbor Vita Corporation Method and apparatus for reading test strips
WO2009092014A1 (fr) 2008-01-18 2009-07-23 Gagnon Peter S Purification améliorée d'anticorps et de fragments d'anticorps par chromatographie sur hydroxyapatite
GB0809995D0 (en) 2008-05-31 2008-07-09 Spd Swiss Prec Diagnostics Gmb Assay device
GB0900669D0 (en) 2009-01-16 2009-02-25 Bed Bugs Ltd Pest control
US20100212213A1 (en) 2009-02-25 2010-08-26 Hope Iii Joe Harold Detection device and method for monitoring bed bug infestation
EP2405746A4 (fr) 2009-03-13 2013-02-13 Fmc Corp Composition pour attirer les punaises
US8577986B2 (en) 2010-04-02 2013-11-05 Microsoft Corporation Mapping RDMA semantics to high speed storage
US20110289824A1 (en) 2010-05-28 2011-12-01 Tai-Teh Wu Compounds, methods, and devices for detecting and/or treating insect infestation
FI20115285A0 (fi) 2011-03-24 2011-03-24 Reagena Ltd Oy Menetelmä pikatestin suorittamiseksi
US9458512B2 (en) 2011-07-05 2016-10-04 Ernest Colaizzi Kit for the detection of bed bugs
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
WO2013096817A2 (fr) 2011-12-23 2013-06-27 Abbott Point Of Care Inc Dispositif d'essai intégré pour détection optique de microréseaux
US9188583B2 (en) 2012-02-29 2015-11-17 Sri International Ectoparasite detection
US20130208114A1 (en) 2013-01-25 2013-08-15 Jody Arthur Balsam Digital Bedbug Indicator: A bedbug insect peripheral electronic detection unit device
GB2524307B (en) 2014-03-20 2016-04-20 Rentokil Initial Plc Apparatus
GB2548944B (en) 2014-04-17 2018-11-28 Z Integrated Digital Tech Inc Electronic test device data communication
KR20180068965A (ko) * 2015-08-31 2018-06-22 에어미드 헬스 그룹 리미티드 신규한 단백질 및 검출 방법
LT3370515T (lt) * 2015-10-21 2022-05-10 Redcoat Solutions, Inc. Patalinių blakių aptikimo įrenginys
RS64530B1 (sr) * 2015-10-21 2023-09-29 Redcoat Solutions Inc Monoklonalna antitela protiv krevetnih stenica i postupci za njihovo pravljenje i upotrebe

Also Published As

Publication number Publication date
HUE063822T2 (hu) 2024-02-28
CA3041460A1 (fr) 2017-04-27
AU2023282327A1 (en) 2024-01-18
WO2017070603A1 (fr) 2017-04-27
HRP20231035T1 (hr) 2023-12-22
AU2016342373B2 (en) 2023-09-21
EP3365367C0 (fr) 2023-06-07
EP3365367A4 (fr) 2019-06-12
EP3365367B1 (fr) 2023-06-07
WO2017070603A9 (fr) 2018-05-17
PL3365367T3 (pl) 2023-10-30
EP4273235A2 (fr) 2023-11-08
MD3365367T2 (ro) 2024-02-29
EP3365367A1 (fr) 2018-08-29
RS64530B1 (sr) 2023-09-29
US10768172B2 (en) 2020-09-08
ES2953484T3 (es) 2023-11-13
MA45831A (fr) 2019-06-12
AU2016342373A1 (en) 2018-06-07
MX2018004986A (es) 2019-01-14
US20170137501A1 (en) 2017-05-18
US20200363405A1 (en) 2020-11-19
EP4273235A3 (fr) 2024-01-17

Similar Documents

Publication Publication Date Title
MA49034B1 (fr) Anticorps anti-lag3
MA38554A3 (fr) Anticorps bispécifiques dirigés contre fap et dr5, anticorps spécifiques dirigés contre dr5 et leurs procédés d'utilisation
MA53356B1 (fr) Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
EA202190983A1 (ru) Новое антитело к с-kit
PH12018500707A1 (en) Anti-human cd19 antibodies with high affinity
MA49599B1 (fr) Anticorps spécifiques à cd47 et pd-l1
MA40682A (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
MA43018B1 (fr) Anticorps anti-pd1 et procédés d'utilisation
MA44659B1 (fr) Anticorps anti-tim-3 et compositions
MA39095A1 (fr) Anticorps et immunoconjugués anti-cd33
MA40609B1 (fr) Agents de liaison cd123 et leurs utilisations
MA38828A1 (fr) Anticorps dirigés contre l'inhibiteur des activateurs du plasminogène de type 1 (pai-1) et leurs utilisations
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201592074A1 (ru) Композиции и способы изменения сигнальной системы вторичного мессенджера
MA37538B1 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
MA33198B1 (fr) Anticorps anti-her di-spécifiques
MA35712B1 (fr) Anticorps anti-htra1 et leurs procédés d'utilisation
NO20084878L (no) Humanisert C-kit antistoff
MA35740B1 (fr) Compositions et procédés pour des anticorps ciblant le facteur p
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
FR3021970B1 (fr) Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
MA34722B1 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
MA33537B1 (fr) Anticorps anti-cdcp1 humanisés